DDInter1667 DDInter833
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Silodosin {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Glycerol phenylbutyrate
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Silodosin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Silodosin {u} (Compound) resembles {v} (Compound) Tamsulosin
Tamsulosin {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Silodosin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Glycerol phenylbutyrate (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Silodosin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Silodosin (Compound) resembles Tamsulosin (Compound) and Tamsulosin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)